Scarica l'app Stockscreener
0.1033
24.51%
-0.208
Precedente Chiudi:
$0.3113
Aprire:
$0.099
Volume 24 ore:
349
Relative Volume:
1.59
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-24.49M
Rapporto P/E:
-0.0311
EPS:
-3.3232
Flusso di cassa netto:
$-4.14M
1 W Prestazione:
-24.51%
1M Prestazione:
-62.29%
6M Prestazione:
-84.44%
1 anno Prestazione:
-93.80%
Intervallo 1D:
$0.099
$0.099
Intervallo di 1 settimana:
$0.099
$0.099
Portata 52W:
$0.099
$0.099
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Nome
Zyversa Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare ZVSA vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.099 | 0 | 0 | -24.49M | -4.14M | -3.3232 |
VRTX
Vertex Pharmaceuticals Inc
|
524.89 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.86 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
180.48 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
975.83 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.07 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zyversa Therapeutics Inc Borsa (ZVSA) Ultime notizie
ZyVersa Therapeutics, Inc. Revenue Breakdown – OTC:ZVSA - TradingView
ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Market Sentiment - Benzinga España
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference - GuruFocus
ZyVersa Therapeutics Transitions to OTC Pink Market - TipRanks
ZyVersa Therapeutics (ZVSA) shifts trading from OTCQB to OTC Pink - Stock Titan
ZyVersa Therapeutics Announces Cost-Cutting Measures and Executive Pay Reductions Amid Efforts to Raise Capital – Form 8-K Filing July 2026 – Minichart - Minichart
ZyVersa Therapeutics (ZVSA) eyes deep cost cuts, asset sales and possible ‘going dark’ - Stock Titan
Form DEF 14A Zyversa Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Zyversa Therapeutics Inc (ZVSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to EBIT forward of ZyVersa Therapeutics, Inc. – OTC:ZVSA - TradingView
ZyVersa Therapeutics, Inc. Actuals & Estimates (OTC:ZVSA) - tradingview.com
Price to earnings forward of ZyVersa Therapeutics, Inc. – OTC:ZVSA - TradingView
Price to sales forward of ZyVersa Therapeutics, Inc. – OTC:ZVSA - TradingView
Enterprise value to EBITDA forward of ZyVersa Therapeutics, Inc. – OTC:ZVSA - TradingView
Zyversa Therapeutics Inc (ZVSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zyversa Therapeutics Inc (ZVSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zyversa Therapeutics Inc (ZVSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zyversa Therapeutics Inc (ZVSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zyversa Therapeutics Inc (ZVSA) Institutional Confidence - TradingKey
Zyversa Therapeutics Inc (ZVSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zyversa Therapeutics Inc (ZVSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zyversa Therapeutics Inc (ZVSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ZyVersa Therapeutics (ZVSA) Q4 2025 earnings summary - Quartr
ZyVersa Therapeutics (ZVSA) Q1 2026 earnings summary - Quartr
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $1.79M — 10-Q Summary - TradingView
ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ZyVersa Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Travel Stocks: Can ZyVersa Therapeutics Inc be recession proof2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Take Profit: What is ZyVersa Therapeutics Incs revenue forecastPortfolio Value Report & Real-Time Price Movement Reports - baoquankhu1.vn
Chart Watch: Can ZyVersa Therapeutics Inc be recession proofNew Guidance & Accurate Trade Setup Notifications - baoquankhu1.vn
ZyVersa Therapeutics Reports Full Year 2025 Financial Results - National Today
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa (NASDAQ: ZVSA) outlines renal and inflammatory pipeline after $18.6M write-down - Stock Titan
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aug Fed Impact: Can ZyVersa Therapeutics Inc be recession proofTrade Entry Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
ZyVersa Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Chipmakers Recap: What is ZyVersa Therapeutics Incs revenue forecast2026 Price Momentum & Weekly High Momentum Picks - baoquankhu1.vn
ZVSA SEC FilingsZyVersa Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Latest ZVSA NewsZyVersa Therapeutics to Participate in a Fi... - Stock Titan
ZyVersa Therapeutics (OTCQB: ZVSA) raises $1M in notes and A-4 warrants - Stock Titan
ZyVersa Therapeutics, Inc. announced that it has received $1 million in funding - marketscreener.com
ZyVersa Therapeutics, Inc. Announces Resignation of Robert G. Finizio from Board and Committee Positions, Effective December 2, 2025 - marketscreener.com
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results - ChartMill
Largest Single-Day Delisting: Nasdaq Removes 10 Companies Including ModivCare and TPI Composites - Stock Titan
ZyVersa Therapeutics to be delisted from Nasdaq, continues trading on OTCQB - Investing.com
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes - manilatimes.net
ZyVersa Therapeutics Highlights Lipidomic Data in Alport - GlobeNewswire
ZyVersa begins phase 2a trial of VAR 200 for diabetic kidney disease - Investing.com Nigeria
ZyVersa Therapeutics, Inc. SEC 10-Q Report - TradingView
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq
Zyversa Therapeutics Inc Azioni (ZVSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.92%
0.76%
Capitalizzazione:
|
Volume (24 ore):